High-Dose Convalescent Plasma for Treatment of Severe COVID-19

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients i...

Full description

Bibliographic Details
Main Authors: Gil C. De Santis, Luciana Correa Oliveira, Pedro M.M. Garibaldi, Carlos E.L. Almado, Julio Croda, Ghislaine G.A. Arcanjo, Érika A.F. Oliveira, Adriana C. Tonacio, Dante M. Langhi, José O. Bordin, Renato N. Gilio, Leonardo C. Palma, Elaine V. Santos, Simone K. Haddad, Benedito P.A. Prado, Marjorie Cornejo Pontelli, Rogério Gomes, Carlos H. Miranda, Maria Auxiliadora Martins, Dimas T. Covas, Eurico Arruda, Benedito A.L. Fonseca, Rodrigo T. Calado
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2022-03-01
Series:Emerging Infectious Diseases
Subjects:
COVID-19
2019 novel coronavirus disease
coronavirus disease
severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
viruses
Online Access:https://wwwnc.cdc.gov/eid/article/28/3/21-2299_article

Internet

https://wwwnc.cdc.gov/eid/article/28/3/21-2299_article

Similar Items